Literature DB >> 25143347

A highly potent agonist to protease-activated receptor-2 reveals apical activation of the airway epithelium resulting in Ca2+-regulated ion conductance.

Cara L Sherwood1, Michael O Daines2, Theodore J Price3, Josef Vagner4, Scott Boitano5.   

Abstract

The airway epithelium provides a barrier that separates inhaled air and its various particulates from the underlying tissues. It provides key physiological functions in both sensing the environment and initiating appropriate innate immune defenses to protect the lung. Protease-activated receptor-2 (PAR2) is expressed both apically and basolaterally throughout the airway epithelium. One consequence of basolateral PAR2 activation is the rapid, Ca(2+)-dependent ion flux that favors secretion in the normally absorptive airway epithelium. However, roles for apically expressed PAR2 activation have not been demonstrated, in part due to the lack of specific, high-potency PAR2 ligands. In the present study, we used the newly developed PAR2 ligand 2at-LIGRLO(PEG3-Pam)-NH2 in combination with well-differentiated, primary cultured airway epithelial cells from wild-type and PAR2 (-/-) mice to examine the physiological role of PAR2 in the conducting airway after apical activation. Using digital imaging microscopy of intracellular Ca(2+) concentration changes, we verified ligand potency on PAR2 in primary cultured airway cells. Examination of airway epithelial tissue in an Ussing chamber showed that apical activation of PAR2 by 2at-LIGRLO(PEG3-Pam)-NH2 resulted in a transient decrease in transepithelial resistance that was due to increased apical ion efflux. We determined pharmacologically that this increase in ion conductance was through Ca(2+)-activated Cl(-) and large-conductance K(+) channels that were blocked with a Ca(2+)-activated Cl(-) channel inhibitor and clotrimazole, respectively. Stimulation of Cl(-) efflux via PAR2 activation at the airway epithelial surface can increase airway surface liquid that would aid in clearing the airway of noxious inhaled agents.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  allergic asthma; asthmagen; ion conductance; lipidated agonist; protease-activated receptor-2

Mesh:

Substances:

Year:  2014        PMID: 25143347      PMCID: PMC4199996          DOI: 10.1152/ajpcell.00257.2014

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  45 in total

Review 1.  Pathogenesis of asthma.

Authors:  Stephen T Holgate
Journal:  Clin Exp Allergy       Date:  2008-06       Impact factor: 5.018

Review 2.  Epithelial cells and airway diseases.

Authors:  David Proud; Richard Leigh
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

Review 3.  Structure, function and pathophysiology of protease activated receptors.

Authors:  Mark N Adams; Rithwik Ramachandran; Mei-Kwan Yau; Jacky Y Suen; David P Fairlie; Morley D Hollenberg; John D Hooper
Journal:  Pharmacol Ther       Date:  2011-01-26       Impact factor: 12.310

4.  β-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway.

Authors:  Heddie L Nichols; Mahmoud Saffeddine; Barbara S Theriot; Akhil Hegde; Daniel Polley; Tamer El-Mays; Harissios Vliagoftis; Morley D Hollenberg; Emma H Wilson; Julia K L Walker; Kathryn A DeFea
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-25       Impact factor: 11.205

5.  PAR2 activation interrupts E-cadherin adhesion and compromises the airway epithelial barrier: protective effect of beta-agonists.

Authors:  Michael C Winter; Sandra S Shasby; Dana R Ries; D Michael Shasby
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-05-19       Impact factor: 5.464

6.  Ligand cross-reactivity within the protease-activated receptor family.

Authors:  B D Blackhart; K Emilsson; D Nguyen; W Teng; A J Martelli; S Nystedt; J Sundelin; R M Scarborough
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

7.  Abrogation of bronchial eosinophilic inflammation and attenuated eotaxin content in protease-activated receptor 2-deficient mice.

Authors:  Toshiaki Takizawa; Masaki Tamiya; Takuya Hara; Jiro Matsumoto; Naohiro Saito; Toru Kanke; Junichi Kawagoe; Yukio Hattori
Journal:  J Pharmacol Sci       Date:  2005-05-07       Impact factor: 3.337

8.  Proteinase-activated receptor 2 activation in the airways enhances antigen-mediated airway inflammation and airway hyperresponsiveness through different pathways.

Authors:  Cory Ebeling; Paul Forsythe; Jason Ng; John R Gordon; Morley Hollenberg; Harissios Vliagoftis
Journal:  J Allergy Clin Immunol       Date:  2005-03       Impact factor: 10.793

Review 9.  Protease-activated receptors and prostaglandins in inflammatory lung disease.

Authors:  Terence Peters; Peter J Henry
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

10.  Acanthamoeba protease activity promotes allergic airway inflammation via protease-activated receptor 2.

Authors:  Mi Kyung Park; Min Kyoung Cho; Shin Ae Kang; Hye-Kyung Park; Dong-Hee Kim; Hak Sun Yu
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

View more
  3 in total

1.  Protease-activated receptor 2 activates airway apical membrane chloride permeability and increases ciliary beating.

Authors:  Derek B McMahon; Alan D Workman; Michael A Kohanski; Ryan M Carey; Jenna R Freund; Benjamin M Hariri; Bei Chen; Laurel J Doghramji; Nithin D Adappa; James N Palmer; David W Kennedy; Robert J Lee
Journal:  FASEB J       Date:  2017-09-05       Impact factor: 5.191

Review 2.  Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones.

Authors:  Tonio Pera; Raymond B Penn
Journal:  Pharmacol Ther       Date:  2016-04-23       Impact factor: 12.310

3.  Targeting of protease activator receptor-2 (PAR-2) antagonist FSLLRY-NH2 as an asthma adjuvant therapy.

Authors:  Marinel Ocasio-Rivera; Frances Marin-Maldonado; Geraline Trossi-Torres; Angely Ortiz-Rosado; Valerie Rodríguez-Irizarry; Eric Rodriguez-Lopez; Sahayra Martínez; Sharilyn Almodóvar; Edu Suarez-Martínez
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.